Cure My Disease

Don't miss your cure!

 Log in / Sign up

Insulin gel and ultrasound: a new combo to fight joint inflammation?

NCT ID NCT07790757

Disease control Sponsor: Deraya University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether applying insulin gel to the skin, combined with therapeutic ultrasound (a technique called phonophoresis), can reduce pain and improve function in people with shoulder joint inflammation. Researchers compare a standard insulin gel with a nano-formulated version that may absorb better. Sixty adults aged 40 to 60 with shoulder inflammation or mild osteoarthritis will receive one of the two gels during physiotherapy sessions. The study measures pain scores, shoulder mobility, and quality of life over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Topical insulin gel (standard and nano-formulated) applied with phonophoresis (ultrasound)
What this could lead to
If it works, this could offer a new, non-invasive way to reduce joint inflammation and improve shoulder function without injections or surgery.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply broadly. Insulin can cause low blood sugar or skin irritation, and the nano-formulation may not absorb as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

60 people

The number who actually took part.

Started

Jul 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40 Years to 60 Years (Adult ) * Patient with diagnosis of shoulder soft tissue inflammation due to SAIS/ * Unilateral or bilateral grade II shoulder osteoarthritis (clinical and imaging diagnosis X-ray). * Patient suffering from shoulder soft tissue inflammation due to SAIS/RCT pain for more than 3 months before enrollment Exclusion Criteria: * Known diabetes mellitus (Type 1 or uncontrolled Type 2) * Skin conditions or open wounds at application site * Hypersensitivity to insulin or gel components * Use of corticosteroids or NSAIDs within 1 week before enrollment Anterior Cruciate Ligament (ACL) and meniscus injury

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Joint inflammation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease osteoarthritis shoulder impingement syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Joint inflammation

Contacts and locations

Locations

  • Deraya university, physiotherapy clinics

    Minya, 05673, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.